Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# alveogene

Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy

## Sitemaps

- [XML Sitemap](https://alveogene.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](https://alveogene.com/) - Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
- [Product Pipeline](https://alveogene.com/product-pipeline/) - Product Pipeline Pipeline AVG-001 is at pre-clinical stage AVG-002 is at candidate selection stage AVG-003 is at candidate selection stage AVG-004 is at discovery stage AVG-002 for Surfactant Protein B Deficiency (SP-B)AVG-002 uses the same proprietary lentiviral vector backbone that is used for all AlveoGene products to deliver the relevant transgene to the lung. AlveoGene
- [Technology Platform](https://alveogene.com/technology-platform/) - Technology Platform THE BENEFITS Technology Overview The InGenuiTy™ includes a proprietary and validated next-generation lentiviral delivery platform specifically targeted for the treatment of respiratory diseases with high unmet need.1Unlike may current gene therapy approaches, which require administration via IV bolus and rely on systemic exposure, respiratory gene therapies developed using InGenuiTy™ can be delivered directly
- [About Us](https://alveogene.com/about-us/) - About us WHO WE ARE Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy Our breakthrough technology aims to transform outcomes by directly addressing the genetic root causes of disease. Welcome to AlveoGene, an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy .Enabled by our proprietary InGenuiTy® platform, our approach
- [News](https://alveogene.com/news/) - News Press Releases New Paper Confirms Safety of InGenuiTy®️ Vector Delivered Directly to the Lungs 07/04/2026 In the recently published Molecular Therapy Advances paper, the InGenuiTy F/HN pseuotyped lentviral platform was assessed in non-human primates. There were no safety issues noted over the seven day period Read More » AlveoGene Provides Latest Company Update 19/12/2025
- [Contact](https://alveogene.com/contact/) - Contact us Get in touch Name Email Company Message Send 46 Woodstock Rd, Oxford OX2 6HTUnited Kingdom

## Dynific Global Templates

- [Presentation block 1](https://alveogene.com/?ae_global_templates=presentation-block) - Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
- [Popup layout](https://alveogene.com/?ae_global_templates=190) - David Hipkiss Executive Chair AlveoGene is led by David Hipkiss, Executive Chair and supported by its 6 academic founders who are core members of the UK Respiratory Gene Therapy Consortium (GTC). David is a biopharmaceutical executive with over 25 years’ experience of building and leading innovative companies, particularly in the respiratory disease area, and a
- [Team post layout](https://alveogene.com/?ae_global_templates=team-post-layout) - David Hipkiss Executive Chair David Hipkiss Executive Chair AlveoGene is led by David Hipkiss, Executive Chair and supported by its 6 academic founders who are core members of the UK Respiratory Gene Therapy Consortium (GTC). David is a biopharmaceutical executive with over 25 years’ experience of building and leading innovative companies, particularly in the respiratory

## team

- [Dr Gerry McLachlan](https://alveogene.com/team/dr-gerry-mclachlan/)
- [Dr Christopher Boyd](https://alveogene.com/team/dr-christopher-boyd/)
- [Professor Stephen Hyde](https://alveogene.com/team/professor-stephen-hyde/)
- [Professor Deborah Gill](https://alveogene.com/team/professor-deborah-gill/)
- [Professor Uta Griesenbach](https://alveogene.com/team/alan/)
- [Professor Eric Alton](https://alveogene.com/team/charlie-hopkiss/)
- [David Hipkiss](https://alveogene.com/team/david-hopkiss/)

## Press Releases

- [New Paper Confirms Safety of InGenuiTy®️ Vector Delivered Directly to the Lungs](https://alveogene.com/press_release/new-paper-confirms-safety-of-ingenuity️-vector-delivered-directly-to-the-lungs/) - In the recently published Molecular Therapy Advances paper, the InGenuiTy F/HN pseuotyped lentviral platform was assessed in non-human primates. There were no safety issues noted over the seven day period of the study. Airway epithelial cell transduction efficiency, as assessed by GFP expression, was ~10% at the dose tested. The study extends earlier findings of
- [AlveoGene Provides Latest Company Update](https://alveogene.com/press_release/alveogene-provides-latest-company-update/) - December 19, 2025 - Oxford UK After a year of steady progress, AlveoGene is pleased to provide an update on the progress of its pipeline of inhaled gene therapy development candidates targeting rare respiratory disease enabled by its InGenuiTy® platform. AlveoGene has generated world leading pre-clinical data in SP-B surfactant protein deficiency (AVG-002), is progressing
- [Update on 2025 Development Progress](https://alveogene.com/press_release/update-on-2025-development-progress/) - Oxford (UK) Since extending our seed financing round earlier this year, the first 4 months of 2025 have seen AlveoGene make good progress in generating world leading pre-clinical data sets for our development programs in Surfactant Protein Deficiencies SP-B and ABCA3, AATD Lung Disease, and IPF enabled by our InGenuiTy® inhaled gene therapy platform. Building
- [ATS 2025 Keynote Shares Exciting Progress in Gene Therapies Using AlveoGene's InGenuiTy® Platform in Cystic Fibrosis - and beyond!](https://alveogene.com/press_release/ats-2025-keynote-shares-exciting-progress-in-gene-therapies-using-alveogenes-ingenuity-platform-in-cystic-fibrosis-and-beyond/) - Delivering the Monday 20 May Keynote Address for the ATS 2025 International Conference, Professor Eric Alton, MD, lead of the UK Respiratory Gene Therapy Consortium (GTC) and Co-Founder of AlveoGene, compared the next wave of advancement in the treatment of cystic fibrosis (CF) with GTC partner Boehringer Ingelheim to a fundamental football (soccer) strategy—shots on
- [AlveoGene on Biotech TV](https://alveogene.com/press_release/alveogene-on-biotech-tv/) - David Hipkiss, Executive Chair of AlveoGene had the great pleasure of talking with Amy Brown of BioTech TV at BioTrinity 2025 in London and outlines how we are using our InGenuiTy® inhaled gene therapy platform to deliver transformational outcomes in rare respiratory disease. Click here for the full interview (11 mins)
- [AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives  Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency](https://alveogene.com/press_release/alveogenes-novel-inhaled-gene-therapy-avg-002-receives-orphan-drug-designation-from-fda-for-lethal-neonatal-surfactant-protein-b-sp-b-deficiency/) - Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Highly encouraging preclinical data highlight the possibility of lifelong treatment from a single administration of AVG-002 with preparations for clinical development underway Follows recent grant of Rare Pediatric Disease Designation from
- [AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency](https://alveogene.com/press_release/alveogene-receives-rare-pediatric-disease-designation-rpdd-from-fda-for-avg-002-its-novel-inhaled-gene-therapy-for-lethal-neonatal-surfactant-protein-b-sp-b-deficiency/) - Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants Clinical estimates for SP-B deficiency have an incidence of 1 in 1 million live births in the US and Europe Highly encouraging preclinical data highlight the possibility of lifelong treatment from a single administration of AVG-002 Preparations for the
- [AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders](https://alveogene.com/press_release/alveogene-launches-to-develop-unique-inhaled-gene-therapies-for-rare-respiratory-disorders/) - New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC) AlveoGene initially aims to leverage proprietary lentiviral gene therapy platform designed and developed by GTC specifically for inhaled delivery First target indication

## presentations

- [NACFC 2022 | S01: Design of Clinical Trials to Evaluate Nucleotide-Based Interventions - YouTube](https://alveogene.com/presentations/nacfc-2022-s01-design-of-clinical-trials-to-evaluate-nucleotide-based-interventions-youtube/)
- [CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression](https://alveogene.com/presentations/cpg-free-plasmids-confer-reduced-inflammation-and-sustained-pulmonary-gene-expression/)
- [Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.](https://alveogene.com/presentations/presentation-1/)
- [Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.](https://alveogene.com/presentations/correction-of-a-chronic-pulmonary-disease-through-lentiviral-vector-mediated-protein-expression/)
- [Lung-targeting lentiviral vector for passive immunisation against influenza.](https://alveogene.com/presentations/lung-targeting-lentiviral-vector-for-passive-immunisation-against-influenza/)
- [Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.](https://alveogene.com/presentations/presentation-2/)

## Events

- [JPM Week 2026 and RESI San Francisco](https://alveogene.com/events/jpm-week-2025-and-resi-san-francisco/) - Executive Chair, David Hipkiss, will be attending JPM 2026 week in San Francisco week beginning 12th January 2026 meeting investors and partners regarding the latest developments and progress of the AlveoGene pipeline of inhaled gene therapy product candidates targeting rare respiratory diseases enabled by AlveoGene's InGenuiTy® platform. He will be attending the main JPM led

## Categories

- [Our Team](https://alveogene.com/category/our-team/)
- [Press Release](https://alveogene.com/category/press-release/)
- [Presentations](https://alveogene.com/category/presentations/)